Cargando…

Identification of Radiomic Signatures in Brain MRI Sequences T1 and T2 That Differentiate Tumor Regions of Midline Gliomas with H3.3K27M Mutation

Background: Radiomics refers to the acquisition of traces of quantitative features that are usually non-perceptible to human vision and are obtained from different imaging techniques and subsequently transformed into high-dimensional data. Diffuse midline gliomas (DMG) represent approximately 20% of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chilaca-Rosas, Maria-Fatima, Contreras-Aguilar, Manuel-Tadeo, Garcia-Lezama, Melissa, Salazar-Calderon, David-Rafael, Vargas-Del-Angel, Raul-Gabriel, Moreno-Jimenez, Sergio, Piña-Sanchez, Patricia, Trejo-Rosales, Raul-Rogelio, Delgado-Martinez, Felipe-Alfredo, Roldan-Valadez, Ernesto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453217/ https://www.ncbi.nlm.nih.gov/pubmed/37627927 http://dx.doi.org/10.3390/diagnostics13162669

Ejemplares similares

Diagnostic Performance of Selected MRI-Derived Radiomics Able to Discriminate Progression-Free and Overall Survival in Patients with Midline Glioma and the H3F3AK27M Mutation
por: Chilaca-Rosas, Maria-Fatima, et al.
Publicado: (2023)

Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics
por: Li, Qian, et al.
Publicado: (2021)

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma
por: Immisch, Lena, et al.
Publicado: (2022)

MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
por: Zhao, Ji-ping, et al.
Publicado: (2022)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

HGG-33. Prognostic factors of H3K27M histone-mutant diffuse midline gliomas in patients ≤18yrs
por: Hu, Qingjun, et al.
Publicado: (2022)

THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION
por: Mosaheb, Mubeen, et al.
Publicado: (2020)

Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma
por: Wang, Stacie S., et al.
Publicado: (2023)

Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars
por: Skinner, Kasey R., et al.
Publicado: (2023)

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
por: Chheda, Zinal S, et al.
Publicado: (2023)

Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures
por: Banan, Rouzbeh, et al.
Publicado: (2021)

Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas
por: Raab, Peter, et al.
Publicado: (2022)

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
por: Immisch, Lena, et al.
Publicado: (2023)

DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS
por: Zhang, Liang, et al.
Publicado: (2020)

Fatal Postpartum Hemorrhage in Diffuse Midline Glioma with H3-K27M Mutation
por: Miyazaki, Takeshi, et al.
Publicado: (2019)

Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas
por: Vuong, Huy Gia, et al.
Publicado: (2022)

DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge
por: Kammler, Gertrud, et al.
Publicado: (2022)

Radiotherapy and radio‐sensitization in H3 (K27M) ‐mutated diffuse midline gliomas
por: Liu, Chao, et al.
Publicado: (2023)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

Dynamic susceptibility contrast perfusion-weighted and diffusion-weighted magnetic resonance imaging findings in pilocytic astrocytoma and H3.3 and H3.1 variant diffuse midline glioma, H3K27-altered
por: Kurokawa, Ryo, et al.
Publicado: (2023)

The H3.3K27M oncohistone antagonizes reprogramming in Drosophila
por: Ahmad, Kami, et al.
Publicado: (2021)

STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma
por: Anderson, Jacob B., et al.
Publicado: (2023)

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
por: Banan, Rouzbeh, et al.
Publicado: (2017)

Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas
por: Welby, John P., et al.
Publicado: (2019)

Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation
por: Hassan, Usman, et al.
Publicado: (2021)

Diffuse midline glioma H3K27M mutation in adult: A case report
por: Bhattarai, Ayush Mohan, et al.
Publicado: (2022)

Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman
por: Low, Justin Thomas, et al.
Publicado: (2021)

Deep Learning for the Prediction of the Survival of Midline Diffuse Glioma with an H3K27M Alteration
por: Huang, Bowen, et al.
Publicado: (2023)

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
por: Jackson, Evangeline R., et al.
Publicado: (2023)

Midline crossing and Slit responsiveness of commissural axons require USP33
por: Yuasa-Kawada, Junichi, et al.
Publicado: (2009)

STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
por: Zhang, Liang, et al.
Publicado: (2022)

IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
por: Tam, Lydia, et al.
Publicado: (2020)

Multiparametric MRI-Based Radiomics Model for Predicting H3 K27M Mutant Status in Diffuse Midline Glioma: A Comparative Study Across Different Sequences and Machine Learning Techniques
por: Guo, Wei, et al.
Publicado: (2022)

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
por: Schreck, Karisa C., et al.
Publicado: (2019)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
por: Wingerter, Arthur, et al.
Publicado: (2021)

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
por: Majzner, Robbie G., et al.
Publicado: (2022)

DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations
por: Gestrich, Catherine, et al.
Publicado: (2022)

A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma
por: Peng, Youheng, et al.
Publicado: (2023)

Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma
por: López, Giselle, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u7mr8theivt1spsshrcv5kcc5a